Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year’s full-year total of $20.3 billion with three quarters still left. The data comes from J.P. Morgan’s Q1 licensing and venture report.
Upfront cash confirms the same trend. Companies put $1.3 billion on the table in Q1, and that’s already nearly halfway to 2025’s $2.9 billion full-year figure. J.P. Morgan called the investment level “just as strong” as recent years, but flagged a shift: GLP-1 and GIP drug deals slowed to just two contracts in Q1, versus eight for all of 2025 and a peak of twelve deals racking up $9.6 billion in 2023.
AstraZeneca wrote the quarter’s largest check: $1.2 billion upfront to Hong Kong’s CSPC Pharmaceutical for exclusive global rights to a long-acting dual GLP-1/GIP drug, three preclinical weight-focused assets, and four collaborative programs. What AstraZeneca gets is a GLP-1/GIP bet with a more-than-$17 billion milestone ceiling, right as that target category cools everywhere else.
Pfizer paid $495 million, upfront plus milestones, for Sciwind Biosciences’ GLP-1 injection, approved in China for type 2 diabetes and under review for obesity. Eli Lilly put $55 million upfront on a preclinical weight-loss program with Nimbus Therapeutics, attaching up to $1.3 billion in milestones.
J.P. Morgan’s conclusion: “deal flow is concentrated in a limited number of high-value transactions.” The firm didn’t name them. AstraZeneca’s $17 billion ceiling on the CSPC deal is the obvious candidate, and why that company is betting on GLP-1/GIP at this scale while deal flow in the category contracts is the quarter’s unanswered question.
— Diana Kowalski